After finishing at $177.33 in the prior trading day, Abbvie Inc (NYSE: ABBV) closed at $167.90, down -5.32%. In other words, the price has decreased by -$9.43 from its previous closing price. On the day, 10411259 shares were traded. ABBV stock price reached its highest trading level at $177.70 during the session, while it also had its lowest trading level at $167.45.
Ratios:
Our goal is to gain a better understanding of ABBV by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 23.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.47. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.87. In the meantime, Its Debt-to-Equity ratio is 5.80 whereas as Long-Term Debt/Eq ratio is at 5.11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 20 ’24 when Donoghoe Nicholas sold 21,082 shares for $176.30 per share. The transaction valued at 3,716,757 led to the insider holds 55,903 shares of the business.
Stewart Jeffrey Ryan sold 58,949 shares of ABBV for $10,539,508 on Mar 18 ’24. The EVP, CHIEF COMMERCIAL OFFICER now owns 60,941 shares after completing the transaction at $178.79 per share. On Mar 01 ’24, another insider, RICHMOND TIMOTHY J., who serves as the EVP, CHIEF HR OFFICER of the company, sold 75,680 shares for $177.27 each. As a result, the insider received 13,415,503 and left with 13,837 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 297.29B and an Enterprise Value of 343.86B. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 61.72, and their Forward P/E ratio for the next fiscal year is 13.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 16.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.46 while its Price-to-Book (P/B) ratio in mrq is 28.62. Its current Enterprise Value per Revenue stands at 6.33 whereas that against EBITDA is 20.02.
Stock Price History:
Over the past 52 weeks, ABBV has reached a high of $182.89, while it has fallen to a 52-week low of $130.96. The 50-Day Moving Average of the stock is 175.52, while the 200-Day Moving Average is calculated to be 154.20.
Shares Statistics:
The stock has traded on average 5.61M shares per day over the past 3-months and 5.03M shares per day over the last 10 days, according to various share statistics. A total of 1.77B shares are outstanding, with a floating share count of 1.76B. Insiders hold about 0.11% of the company’s shares, while institutions hold 71.94% stake in the company. Shares short for ABBV as of Mar 15, 2024 were 14.69M with a Short Ratio of 2.62, compared to 14.75M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.83% and a Short% of Float of 0.83%.
Dividends & Splits
In the trailing 12 months, ABBV’s forward annual dividend rate was 5.99, compared to 5.99 this year. Against a Trailing Annual Dividend Yield of 3.38%, it implies a Forward Annual Dividend Yield of 3.44%. The stock’s 5-year Average Dividend Yield is 4.45.
Earnings Estimates
Its stock is currently analyzed by 16 different market analysts. On average, analysts expect EPS of $2.33 for the current quarter, with a high estimate of $2.4 and a low estimate of $2.26, while EPS last year was $2.46. The consensus estimate for the next quarter is $2.8, with high estimates of $2.92 and low estimates of $2.62.
Analysts are recommending an EPS of between $11.46 and $10.85 for the fiscal current year, implying an average EPS of $11.19. EPS for the following year is $12.21, with 24 analysts recommending between $13.05 and $11.5.
Revenue Estimates
14 analysts predict $11.97B in revenue for the current quarter. It ranges from a high estimate of $12.59B to a low estimate of $11.86B. As of the current estimate, Abbvie Inc’s year-ago sales were $12.22B, an estimated decrease of -2.10% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $13.52B, a decrease of -2.50% less than the figure of -$2.10% in the same quarter last year. There is a high estimate of $13.82B for the next quarter, whereas the lowest estimate is $12.99B.
A total of 25 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $55.38B, while the lowest revenue estimate was $53.86B, resulting in an average revenue estimate of $54.56B. In the same quarter a year ago, actual revenue was $54.32B, up 0.40% from the average estimate. Based on 24 analysts’ estimates, the company’s revenue will be $57.92B in the next fiscal year. The high estimate is $60.8B and the low estimate is $55.72B. The average revenue growth estimate for next year is up 6.20% from the average revenue estimate for this year.
